🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

UnitedHealth Group shares get price target boost, Hold rating by Jefferies

EditorNatashya Angelica
Published 17/07/2024, 16:54
UNH
-

On Wednesday, UnitedHealth Group (NYSE:UNH) saw its stock price target significantly increased by Jefferies from the previous $481.00 to $647.00. The firm has maintained a Hold rating on the healthcare giant's stock. This revision comes amid expectations of a favorable growth outlook for the company in 2025, which includes strong Medicare Advantage (MA) growth with better margins.

The analyst from Jefferies believes that UnitedHealth is on track to achieve a unique accomplishment of strong MA growth at improved margins in 2025, which is anticipated to support the growth of OptumHealth and enhance the company's valuation.

The updated outlook takes into consideration various factors, including recent elections and conservative bidding, which are seen as contributing to an improving growth trajectory for the upcoming year.

UnitedHealth Group's performance, according to the analyst's expectations, could lead to a revisiting of its five-year relative multiple of approximately 1x the S&P 500. This scenario would represent an 18% upside potential for the stock. The analyst's comments reflect a sentiment that the near-term medical loss ratio (MLR) outlook, while not entirely transparent, is "clear enough" following the first and second quarters to shift focus to the growth prospects for 2025.

The price target adjustment is based on the premise that UnitedHealth Group will continue to expand its Medicare Advantage segment while simultaneously fostering the growth of OptumHealth, a diversified health services group under the UnitedHealth umbrella. This is expected to play a crucial role in lifting the company's overall valuation.

UnitedHealth Group, a diversified health care company, offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services, and Optum, which delivers information and technology-enabled health services. The company's stock is traded on the New York Stock Exchange under the ticker symbol UNH.

In other recent news, UnitedHealth Group has been the subject of considerable attention from financial analysts. RBC Capital raised its price target for UnitedHealth to $615, citing strong second-quarter earnings, particularly in its Medicare business.

Truist Securities also increased its price target for the healthcare giant to $640, maintaining a Buy rating based on robust core trends and reaffirmed full-year 2024 guidance. Jefferies upgraded UnitedHealth stock from a Hold to a Buy, setting a new price target of $647, based on a favorable growth outlook for 2025.

TD Cowen reiterated its Buy rating on UnitedHealth stock, maintaining a price target of $546, indicating confidence in the company's performance despite ongoing trends in Medicare Advantage and Medicaid. Recent developments for UnitedHealth also include the election of its Board of Directors and the authorization of a $2.10 per share cash dividend during its 2024 annual shareholder meeting.

In addition, Kevin Hern, representative for Oklahoma's 1st congressional district, has made investments in UnitedHealth through dividend reinvestment as part of a diversified investment strategy.

The company is also under scrutiny from the Federal Trade Commission over its pharmacy-benefit management pricing strategies. UnitedHealth recently experienced a cyberattack on its Change Healthcare (NASDAQ:CHNG) unit, compromising the private data of an estimated one-third of Americans.

InvestingPro Insights

Following the Jefferies price target increase for UnitedHealth Group (NYSE:UNH), a look at the real-time data from InvestingPro reveals additional insights into the company's financial health and market performance. UnitedHealth Group boasts a robust market capitalization of $505.17 billion, emphasizing its significant presence in the healthcare sector.

The company's P/E ratio stands at 34.05, reflecting a premium valuation compared to the broader market, which may be justified by its consistent performance and growth prospects. UnitedHealth has demonstrated a solid revenue growth of 10.59% over the last twelve months as of Q2 2024, indicating its ability to expand its operations effectively.

An InvestingPro Tip highlights the company's track record of raising its dividend for 14 consecutive years, showcasing its commitment to returning value to shareholders. Moreover, UnitedHealth is a prominent player in the Healthcare Providers & Services industry, which could provide investors with confidence in the stability and future prospects of the company.

For those seeking deeper analysis and additional insights, there are over 16 InvestingPro Tips available for UnitedHealth Group at https://www.investing.com/pro/UNH. Readers can use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking a wealth of information to inform their investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.